

Nomination for President*

Annual General Meeting, Tuesday 13 May 2025 Joint Congress of ESPE and ESE 2025, Copenhagen, Denmark

Form A

*President-elect for 2025-2027 and President 2027-2029

Please return to: Professor M Zatelli, Secretary, European Society of Endocrinology, Redwood House, Brotherswood Court, Great Park Road, Bradley Stoke, Bristol, BS32 4QW, UK or email to info@ese-hormones.org

Please refer the <u>Information on the role of an ESE Executive Committee member</u> for detailed information on the role and time commitment. Important information is also detailed in the Trustees' responsibilities: Key points for Executive Committee candidates.

	Closing date: Monday 6 January 2025		
1	Name of Nominee:	Mirjam Christ-Crain	
2	Nationality:	Swiss	
3	Email address:	Mirjam.christ-crain@usb.ch	
4	Current position and geographical location:	Deputy Head, Department of Endocrinology, University hospital Basel, Switzerland	
5	Speciality in endocrinology/Main field of expertise:	Neuroendocrinology, Pituitary, Endocrinology of critical illness	
6	Basic, clinical or both:	Clinical	
7	Give details of current or previous committee experience in a national society of endocrinology or a European speciality society:	European Society of Endocrinology Member of the Executive Committee 2020-2024 Chair of the Education committee ESE 2020-2024 Member of the working group "new ESE Endocrinology curriculum and training recommendations 2022-2024 European Neuroendocrine Association Member of the POC of 21st Congress 2024 International Society of Endocrinology Member of the POC of ICE congress 2020 Swiss Society of Endocrinology and Diabetes Member of the Executive Committee 2009-2019	
8	Give details of experience as an editor or member of an editorial board:	European Journal of Endocrinology Associate editor since 2020 Journal of Clinical Endocrinology and Metabolism Member of the editorial Board 2020-2024 Best Pract Res Clin Endocrinol Metab Guest editor on "Diabetes insipidus" in 2020	
9	List (max) 10 papers that were published in international journals within the last 6 years. Note: journals to have an impact factor of 2.0 or above.	 Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency. Atila C, Refardt J, Christ-Crain M. Nat Rev Endocrinol. 2024 Aug; 20(8):487-500 Hypopituitarism. Fleseriu M, Christ-Crain M, Langlois F, Gadelha M, Melmed S. Lancet. 2024 Jun 15;403(10444):2632-2648 Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. Refardt J, Atila C, Chifu I, Ferrante E, Erlic Z, Drummond JB, Indirli R, Drexhage RC, Sailer CO, Widmer A, Felder S, Powlson AS, Hutter N, Vogt DR, Gurnell M, Soares BS, Hofland 	

J, Beuschlein F, Fassnacht M, Winzeler B, Christ-Crain M. N Engl J Med. 2023 Nov 16;389(20):1877-1887. 4) Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, Sailer CO, Eckert A, Heinrichs M, Liechti ME, Christ-Crain M. Lancet Diabetes **Endocrinol. 2023** Jul;11(7):454-46 5) Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. Refardt J, Imber C, Nobbenhuis R, Sailer CO, Haslbauer A, Monnerat S, Bathelt C, Vogt DR, Berres M, Winzeler B, Bridenbaugh SA, Christ-Crain M. J Am Soc Nephrol. 2023 6) Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey. Atila C, Loughrey PB, Garrahy A, Winzeler B, Refardt J, Gildroy P, Hamza M, Pal A, Verbalis JG, Thompson CJ, Hemkens LG, Hunter SJ, Sherlock M, Levy MJ, Karavitaki N, Newell-Price J, Wass JAH, Lancet Diabetes Endocrinol. Christ-Crain M. Oct;10(10):700-709 7) A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia. Winzeler B, Sailer C, Coynel D, Zanchi D, Vogt D, Urwyler S, Refardt J, Christ-Crain M. J Clin Invest 2021 Oct 15;131(20) e151800. doi: 10.1172/JCI151800 8) Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Winzeler B, Cesana-Nigro N, Refardt J, Vogt DR, Imber C, Morin B, Popovic M, Steinmetz M, Sailer CO, Szinnai G, Chifu I, Fassnacht M, Christ-Crain M. Lancet. 2019 Aug 17;394(10198):587-595 9) Diabetes insipidus. Christ-Crain M, Bichet DG, Fenske WK, Goldman MB, Rittig S, Verbalis JG, Verkman AS. Nat Rev Dis Primers. 2019 Aug 8;5(1):54 10) A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A Jr, Drescher T, Bilz S, Vogt DR, Malzahn U, Kroiss M, Christ E, Henzen C, Fischli S, Tönjes A, Mueller B, Schopohl J, Flitsch J, Brabant G, Fassnacht M, Christ-**Crain M. N Engl J Med. 2018** Aug 2;379(5):428-439 I have received funding of appr **10 Mio Euro** within the last 8 years of the 10 Give details of any experience with EU Swiss National Science Foundation to perform European investigatorfunding: initiated Multicenter trials Multicenter intervention trial to investigate a targeted hyponatremia correction versus standard care, involved centers: Switzerland, Germany, Netherlands, Italy, Croatia Multicenter intervention trial to investigate the effect of the SGLT-2 inhibitor empagliflozin versus placebo in patients with the syndrome of inadequate antidiuresis (SIAD), involved centers: Switzerland, Germany, Netherlands

	 Multicenter intervention trial to investigate the effect of Oxytocin treatment versus placebo in patients with AVP deficiency, involved centers: Switzerland, Germany, Netherlands, France Multicenter diagnostic study to investigate hypertonic saline versus arginine stimulation in patients with AVP deficiency, involved centers: Switzerland, Germany, UK, Italy, Brazil
--	--